Provided by Tiger Trade Technology Pte. Ltd.

Evommune

14.02
+0.45003.32%
Post-market: 14.020.00000.00%19:32 EDT
Volume:326.55K
Turnover:4.57M
Market Cap:508.82M
PE:-5.37
High:14.25
Open:13.74
Low:13.70
Close:13.57
52wk High:33.20
52wk Low:10.47
Shares:36.29M
Float Shares:19.98M
Volume Ratio:0.79
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6090
EPS(LYR):-11.2228
ROE:-52.11%
ROA:-31.99%
PB:1.83
PE(LYR):-1.25

Loading ...

Company Profile

Company Name:
Evommune
Exchange:
NYSE
Establishment Date:
2020
Employees:
48
Office Location:
1891 Page Mill Road,Palo Alto,California,United States
Zip Code:
94304
Fax:
- -
Introduction:
Evommune, Inc. is a company incorporated in Delaware in April 2020 and headquartered in Palo Alto, California. It is a clinical-stage biotechnology company focused on developing innovative therapies targeting key pathogenic drivers of chronic inflammatory diseases. Its initial clinical development programs are focused on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.

Directors

Name
Position
Benjamin F. McGraw, III
Chairman of the Board and Director
Luis Peña
President,Chief Executive Officer and Director
Eugene A. Bauer
Chief Medical Officer and Director
Arthur Kirsch
Director
David E. Cohen
Director
Derek DiRocco
Director
Felice Verduyn van Weegen
Director
Francois Beaubien
Director
Robert Hopfner
Director
Yuexin Yu
Director

Shareholders

Name
Position
Luis Peña
President,Chief Executive Officer and Director
Kyle Carver
Chief Financial Officer
Eugene A. Bauer
Chief Medical Officer and Director
Gregory S. Moss
Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer
Janice Drew
Executive Vice President,Operations
Jeegar Patel
Chief Scientific Officer